Franz Woltering

Effect of certolizumab pegol on signs and symptoms in patients with psoriatic arthritis: 24-week results of a Phase 3 double-blind randomised placebo-controlled study (RAPID-PsA)

Philip J. Mease, Roy Fleischmann, Atul Deodhar et al. · Annals of the Rheumatic Diseases · 2013 · 453 citations · Full text

Safety and efficacy of rozanolixizumab in patients with generalised myasthenia gravis (MycarinG): a randomised, double-blind, placebo-controlled, adaptive phase 3 study

Vera Bril, Artur Drużdż, Julian Großkreutz et al. · The Lancet Neurology · 2023 · 227 citations

Clinical Trials, Generalised Myasthenia Gravis, Pharmacotherapy +3

Efficacy and Safety of Rozanolixizumab in Moderate to Severe Generalized Myasthenia Gravis

Vera Bril, Michael Benatar, Henning Andersen et al. · Neurology · 2020 · 136 citations · Full text

Phase 2 multiple-dose study of an FcRn inhibitor, rozanolixizumab, in patients with primary immune thrombocytopenia

Tadeusz Robak, Maciej Kaźmierczak, Isidro Jarque et al. · Blood Advances · 2020 · 107 citations · Full text

Immunohematology, Isolated Thrombocytopenia, Immunodeficiencies +23

Effect of different imputation approaches on the evaluation of radiographic progression in patients with psoriatic arthritis: results of the RAPID-PsA 24-week phase III double-blind randomised placebo-controlled study of certolizumab pegol

D. van der Heijde, Roy Fleischmann, J. Wollenhaupt et al. · Annals of the Rheumatic Diseases · 2013 · 77 citations · Full text